Combining regenerative therapy with light treatment can effectively promote hair growth.
December 2023 in “Journal of health and rehabilitation research” Oral Apremilast effectively treats alopecia areata in most patients.
44 citations
,
August 1996 in “Drugs & Aging” Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.
3 citations
,
January 2015 in “Nasza Dermatologia Online” Some treatments for autoimmune hair loss work, but JAK inhibitors like tofacitinib are promising for regrowth.
September 2025 in “Journal of the American Academy of Dermatology”
December 2024 in “Drug Discoveries & Therapeutics” Baricitinib-loaded EVs help hair regrowth in alopecia areata by reducing inflammation and promoting hair follicle regeneration.
July 2025 in “Journal of Cosmetic Dermatology” Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
22 citations
,
October 2000 in “British Journal of Haematology” Non-myeloablative stem cell transplants are a promising, less toxic option for older or weaker patients, with fewer side effects and good outcomes.
September 2024 in “Journal of the American Academy of Dermatology” Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.
8 citations
,
January 2017 in “Dermatology online journal” Tofacitinib helped psoriasis but not alopecia universalis, needing more research.
1 citations
,
March 2023 in “Skin” Baricitinib helps patients with severe alopecia areata regrow hair.
3 citations
,
January 2011 in “Yearbook of Dermatology and Dermatologic Surgery”
6 citations
,
November 2019 in “The application of clinical genetics” The study found that a specific genetic variation in the TNFα gene is significantly linked to Alopecia Areata in the Jordanian Arab population.
April 2025 in “Frontiers in Immunology” Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
January 2024 in “Wiadomości Lekarskie” AI can help diagnose Follicular Lymphoma by accurately identifying specific cell types.
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
May 2025 in “International Journal of Trichology” Topical tofacitinib may help regrow hair in children with alopecia totalis.
April 2025 in “Scientific Reports” Astragaloside A may help fight lung cancer by targeting specific proteins.
May 2024 in “Drugs & Therapy Perspectives” New treatments like JAK inhibitors offer hope for better alopecia areata management.
10 citations
,
May 2017 in “Wound Repair and Regeneration” Overexpression of ALK2 in hair follicles disrupts skin development and slows wound healing.
2 citations
,
November 2018 in “Destaques Acadêmicos” Microneedling showed the most significant results for treating hair thinning in Androgenetic Alopecia.
December 2020 in “ID on line. Revista de psicologia” Low-power laser therapy with essential oils effectively promotes new hair growth in male pattern baldness.
September 2023 in “PubMed” Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
May 2023 in “The Journal of Immunology” Expanding CD4+ Tregs can stop hair loss in alopecia areata.
January 2026 in “Forum Dermatologicum” JAK inhibitors and combination therapies show promise for treating severe alopecia areata.
4 citations
,
June 2025 in “Cell Reports” Clonally expanded CD8+ T cells cause alopecia areata.
November 2022 in “Journal of Investigative Dermatology” ILC1-like cells can cause alopecia areata by affecting hair follicles.
January 2026 in “Dermatologic Therapy” Photobiomodulation therapy effectively promotes hair regrowth and improves quality of life in alopecia areata without side effects.